 |
HCVJEVCI
HEPATITIS C - UNIČIMO GA !
|
| Poglej prejšnjo temo :: Poglej naslednjo temo |
| Avtor |
Sporočilo |
kana
Gost
|
 Objavljeno: 02 Okt 2006 13:23 Naslov sporočila: Upanje za "non-responderje"... |
 |
|
Se opravicujem, ker odpiram novo temo ampak bom pozabila ce zdaj ne objavim.. 
Raziskave so pokazale, da tisti ki do zdaj niso reagirali na kombinacijo interferon+ribavarin bolje reagirajo na kombinacijo treh zdravil interferon+ribavarin+amantadine...
| Citiram: | Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed SN, Adeleine P, Trepo C; French Multicenter Group.
Department of Hepato-gastroenterology, Hotel-Dieu, 1 place de l'Hopital, 69288 Lyon Cedex 02, France.
BACKGROUND/AIMS: To determine whether addition of amantadine to pegylated interferon/ribavirin improved response rates among chronic hepatitis C patients, non-responders to interferon/ribavirin and study the dynamic of response. METHODS: In a double blind, multicenter, randomized trial, 200 non-responder patients received pegylated interferon 1.5 microg/kg per week and ribavirin 800-1200 mg/day, plus either amantadine 200 mg/day or placebo for 48 weeks. Endpoints were virological responses, ALT normalization, and histological benefit overtime. RESULTS: Twenty percent of all patients achieved a sustained virological response (SVR). This rate was 8% higher in the triple therapy group (24%) compared with the double therapy group (16%) (P = 0.22). A better virological response rate at week 24 was observed in the triple regimen group (43 vs 29%; P = 0.06), which was lost at week 48 suggesting viral escape. The biochemical response rate was also significantly higher with triple therapy at week 12 (63 vs 49%; P = 0.05) and week 24 (64 vs 49%; P = 0.03). Fibrosis stabilized or improved in 77% of all patients. CONCLUSIONS: Re-treatment of interferon/ribavirin non-responder patients should be encouraged since a substantial proportion benefits from re-treatment with pegylated interferon/ribavirin +/- amantadine. In triple therapy involving amantadine, a time wise response and an increased SVR rate in subgroups less prone to viral breakthrough suggest clues for existing controversies.
|
Vir: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16426697 |
|
| Nazaj na vrh |
|
 |
kana
Gost
|
|
| Nazaj na vrh |
|
|
ELI
Administrator foruma
Pridružen/-a: 31.05. 2006, 18:14
Prispevkov: 824
Kraj: Ljubljana
|
| Objavljeno: 02 Okt 2006 13:57 Naslov sporočila: |
|
|
Kana,
Ni problema - to je zelo pomembna novica za tiste,pri katerih terapija interferon-ribavirin ne uspe. O Amantadinu sem dosti brala,ko sem se jaz zdravila - poskušali so zdraviti samo z Amantadinom ampak je bilo neuspešno. Če bi pa ta trojna kombinacija uspela bi bilo pa super.
pozdravček, eli....  |
|
| Nazaj na vrh |
|
|
sandra
Gost
|
| Objavljeno: 02 Okt 2006 21:00 Naslov sporočila: |
|
|
| Kana hvala za dobro novico.To pomeni še več upanja za nas vse.Zato folk ne obupajmo.Je ozdravljivo.Samo moremo verjeti. |
|
| Nazaj na vrh |
|
|
|
|
Ne, ne moreš dodajati novih tem v tem forumu
Ne, ne moreš odgovarjati na teme v tem forumu
Ne, ne moreš urejati svojih prispevkov v tem forumu
Ne, ne moreš brisati svojih prispevkov v tem forumu
Ne ne moreš glasovati v anketi v tem forumu
|
|
Pogosta vprašanja
Išči
Seznam članov
Skupine uporabnikov
RSS Feed
Registriraj se
Tvoj profil
Zasebna sporočila
Prijava
